

6 September 2023

## Usage of Ruxolitinib

### **Question:**

I am researching real-world usage of Ruxolitinib. Could you please tell me how many patients your Trust has treated in the past 6 months (for any disease) with the following:

Ruxolitinib – any strength  
Ruxolitinib 5mg tablets or Ruxolitinib 10mg tablets

In case you are able to link Ruxolitinib usage to disease, could you also provide the number of patients treated in the last 6 months for myelofibrosis ONLY with

Ruxolitinib – any strength  
Ruxolitinib 5mg tablets or Ruxolitinib 10mg tablets

### **Response:**

Unfortunately, Belfast Trust Pharmacy JAC System (Pharmacy software solution for medicines management) is unable to provide this level of detail.

The Cancer & Specialist Medicine service do not currently collect this information. To provide the information would require a manual trawl of individual patient records.

The Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.